Introduction
The prevalence of type 2 diabetes is increasing worldwide, with the number of affected individuals expected to double by 2050. 1 Diabetes is a leading cause of kidney failure, blindness, leg amputation, and myocardial infarction. There is evidence that early control of blood glucose can help prevent these diabetes-related complications. 2 Current treatment is based on a stepwise approach starting with changes in lifestyle and progressively introducing oral antidiabetic agents, with the aim of maintaining glycated hemoglobin (HbA 1c ) levels below a defined target. This target is defined according to the patient's characteristics. [3] [4] [5] In the current paradigm, insulin is usually considered to be the last step in treatment intensification.
Prescribing insulin at later stages of type 2 diabetes disease progression has recently been challenged, arguing that a delay in insulin initiation may affect the patient's long-term prognosis. Indeed, it is well known that elevated fasting plasma glucose levels are primarily due to an increase in hepatic glucose production, secondary to an insufficient endogenous insulin secretion needed to overcome insulin resistance. 6 Furthermore, there is a well documented decline in insulin secretion due to beta cell exhaustion, and it has been suggested that early use of insulin may suppress inflammation and glucolipotoxicity, which results in autoaggravation of the disease. 7 However, early introduction of insulin may represent a challenge with regard to the well known "psychological insulin resistance" status affecting both patients and doctors. This results in delayed insulin prescription when it would be appropriate according to current guidelines. Psychological insulin resistance, 8 which represents a typical case of clinical inertia, [9] [10] [11] [12] [13] [14] may be due in part, on the side of the doctor, to the supposed effect of insulin treatment on patients' quality of life which may hinder future adherence. [15] [16] [17] [18] [19] On the other hand, nonadherence to long-term therapies also represents a barrier to the efficiency of care, [20] [21] [22] even if it seems that doctors' clinical inertia is actually more frequent than patient nonadherence. 23 In this context, the objective of this study using data from the National Health and Wellness Survey (NHWS) carried out in France was to identify the intrinsic and extrinsic determinants of insulin prescription, and more specifically of early insulin initiation (being defined as 5 years or less following diagnosis) in type 2 diabetes, and to evaluate the impact of insulin therapy on mental and physical quality of life and patient adherence.
Materials and methods national health and Wellness survey sample
The study sample and data were taken from the 2008, 2010, and 2011 waves (2008, n = 15,457; 2010, n = 15,501; 2011, n = 15,000) of the French NHWS. The NHWS is an annual Internet-based questionnaire developed by Kantar Health and the Ailment Panel of Lightspeed Research. It is a crosssectional study of subjects aged 18 years or older, conducted with a strictly identical methodology for the 3 years (2008, 2010, and 2011) . Only a small proportion of individuals from the sample were common between waves (approximately one in five) and data from recent participation were retained.
The primary objective of the NHWS is to provide a comprehensive database of epidemiological and treatment information, health care attitudes, behaviors, demographic and disease characteristics, and health-related outcomes. The 2011, 2010, and 2008 surveys employ a stratified random sample (with both sex and age group quotas), in order to replicate the demographic composition of each of the population of each individual country. Representation of NHWS data has been validated against reliable sources, including government agencies' health statistics and nonaffiliated third parties. Results are projected to reflect the total population in each country using known population characteristics. In France, data are weighted by sex and age using the United States Bureau of the Census and Organization for Economic Cooperation and Development.
A self-administered questionnaire is completed by a sample population identified through a web-based consumer panel. All data from the NHWS are self-reported by participating respondents. All respondents received and agreed with the informed consent form provided, and the study was approved by the Essex Institutional Review Board (Lebanon, NJ, USA). Of the total 45,958 persons recruited (three waves deduped study sample), 1,933 respondents were identified as reporting a physician diagnosis of type 2 diabetes, comprising 591 from the 2008 wave, 649 from 2010, and 693 from 2011 (respectively 3.8%, 4.2%, and 4.3% of the general population of adults). All unique respondents diagnosed with type 2 diabetes currently using insulin or oral bitherapy or tritherapy at the time of assessment were included (n = 713, see Table 1 ); this choice was justified by the fact that, both according to current guidelines and as a result of doctors' and patients' psychological insulin resistance, patients treated with dual therapy or tritherapy have a greater likelihood of being switched to insulin than those treated with monotherapy.
Measures and survey instruments independent variables
We first compared all patients on bitherapy or tritherapy (n = 443) and all insulin users (n = 270). Second, we compared early and late initiation of insulin: based on calcula- tion of the number of years between diagnosis of type 2 diabetes and initiation of insulin, with early insulin defined as 5 years or less (n = 143). The control group (n = 124) consisted of those patients who were prescribed insulin later. Third, another independent variable of interest was the duration of insulin use, using a median split of the number of years using insulin, ie, 5 years or less versus 6 years or more (Table 1) .
covariates
Regardless of how early initiation is defined, great care must be taken in isolating the effect of early initiation or beginning insulin on health outcomes, given the crosssectional, observational nature of the NHWS. Insulin can be initiated for a variety of reasons as physicians attempt to manage risk in their patients. Irrespective of outcomes, the model included the following predictors: age/age at diagnosis, duration of type 2 diabetes, sex, education, household income, and employment type (see Table 2 ). Medication adherence was assessed using the Morisky Medication Adherence Scale (MMAS). The MMAS consists of four yes/no questions that assess the general adherence of using prescribed medication. 25 The total score varies from 0 to 4, with lower scores indicating greater adherence; adherence (0) versus nonadherence (1-4) were compared. Medication adherence data was only collected in 2010 and 2011. Therefore, the sample size is smaller compared with the other metrics.
statistical analyses
Bivariate and multivariate analyses were conducted. Bivariate analyses were used to compare data between patients on insulin versus patients on oral bitherapy or tritherapy, and data between patients starting early insulin versus late insulin. Chi-square tests were used for categorical variables and the t-test was used for continuous variables to determine differences between groups.
The independent variables were used in multivariable analyses to identify differences between two groups on quality of life outcome measures and adherence after adjusting for differences in demographics and patient characteristics. This was achieved by regression modeling (logistic and multivariable linear regressions). For all statistical tests, the applied comparison-wise significance level was a P value , 0.05.
Results

Determinants of insulin prescription
Patients on insulin versus patients on oral bitherapy or tritherapy
The average age of patients on insulin (n = 270) and on oral bitherapy or tritherapy (n = 443) was comparable (59.14 years versus 60.27 years) while 61.48% and 69.98%, respectively, were men (P = 0.021). Those on insulin were younger at diagnosis (mean 44.6 years versus 49.5 years, P , 0.0001), and the average duration of type 2 diabetes since diagnosis was longer (14.7 years versus 10.75 years, P , 0.0001). Socioeconomically, they more likely to have less income (,€20,000/year: 32.59% versus 21.90%, P = 0.0021), and were less likely to have a higher level of secondary education (24.44% versus 33.41%, P = 0.0096). In terms of clinical characteristics, they were less frequently overweight (31.85% versus 39.95%, P = 0.0277), had a higher Charlson comorbidity index (0.6 versus 0.33, P = 0.0017), significantly more likelihood of myocardial infarction (P = 0.0422), and presented more microvascular and macrovascular complications (P , 0.0001). They were more often poorly controlled (HbA 1c .7%: 32.96% versus 17.61%, P , 0.0001). They were more frequently followed up by a prescribing physician who was not a general practitioner (77.78% versus 24.15%, P , 0.0001) and were more often aware of their HbA 1c level (P , 0.0001). Finally, they were significantly more adherent (adherence MMAS = 0: 82.61% versus 72.36%, P = 0.0066). We did not observe differences in terms of healthy lifestyle (physical exercise), risk factors (alcohol, smoking), or fear about needles ( Table 3) .
As shown in Table 4 , a logistic regression was run to assess factors that influence insulin use versus oral bitherapy or tritherapy use. The probability of taking insulin was raised if the patient presented the following factors, in decreasing order: retinopathy or macular edema (odds ratio [OR] 3.035, 95% confidence interval [CI] 1.317-6.992, P = 0.0091) and neuropathic pain (OR 2.095, 95% CI 1.149-3.822, P = 0.0159). On the contrary, patients treated by a specialist had a 12 times greater odds of using insulin (OR 0.083, 95% CI 0.054-0.128, P , 0.0001) versus patients followed up by a prescribing general practitioner, and those who had an income $€50,000 per annum were less likely to receive insulin (OR 0.26, 95% CI 0.119-0.567, P = 0.0007). Finally, older age at diagnosis was associated with less likelihood of being put on insulin (OR 0.974, 95% CI 0.955-0.994, P = 0.0117). Overweight and unknown fasting glucose were marginally significant predictors of oral use.
Factors influencing early initiation of insulin
As shown in Table 5 , patients were younger in the type 2 diabetes early insulin initiation group (n = 143) than in the type 2 diabetes initiated later with insulin group (n = 124), ie, 56.37 years versus 62.6 years (P , 0.0001) and this was confirmed in the younger age group at initiation of insulin (47.42 years versus 56.86 years, respectively, P , 0.0001). Fewer males initiated insulin early compared with the late insulin initiation group (55.24% versus 68.55% respectively, P < 0.025). Socioeconomically, they had a lower income (,€20,000 per year: 38.46% versus 26.61%, P = 0.0384). In terms of lifestyle, they were more likely to smoke (23.08% versus 10.48%, P = 0.0053), and reported less controlled type 2 diabetes (HbA 1c .7%, 25.87% versus 41.94%, P , 0.0057).
As shown in Table 6 , a logistic regression was run to assess factors that influence early initiation of insulin (#5 years) versus late initiation using a median split ( Notes: *Assessed using the MMAs. The MMAs includes four items ("do you ever forget to take your medicine?"; "are you careless at times about taking your medicine?"; "when you feel better do you sometimes stop taking your medicine?"; and "sometimes if you feel worse when you take your medicine, do you stop taking it?"). All items have a dichotomous yes/no response scale and are summed to form a total score (which varies from 0 to 4, with lower scores indicating greater adherence). Abbreviations: BMi, body mass index; MMAs, Morisky Medication Adherence scale; sD, standard deviation; hA, heart attack; TiA, transient ischemic attack; PcP, primary care physician. Abbreviations: GP, general practitioner; OR, odds ratio; SE, standard error; LCL, lower confidence limit; UCL, upper confidence limit. P = 0.0191, respectively). Inversely, high income (€20,000-€50,000) was a significant predictor of late insulin initiation (OR 0.452, 95% CI 0.239-0.856, P = 0.0148). It should be noted that a currently uncontrolled HbA 1c level was a marginally significant predictor of late insulin initiation (OR 0.549, 95% CI 0.28-1.076, P = 0.0807).
A logistic regression was also run to assess the factors that influence early insulin initiation versus the subgroup of uncontrolled oral bitherapy or tritherapy users. From Table 6 , we can see that high income was also associated with late insulin initiation, with patients receiving an income of $€50,000 per annum having lower odds of being put on insulin early (OR 0.26, 95% CI 0.072-0.94, P = 0.0399). It should be noted that the odds of early initiation of insulin therapy prescribed by an endocrinologist or diabetologist were 9.9 greater compared with a primary care physician (OR 0.101, 95% CI 0.05-0.204, P , 0.0001).
Predictors of control of type 2 diabetes
As shown in Table 7 , when comparing controlled patients (all therapies, n = 224) versus uncontrolled (HbA 1c ,7%) patients (n = 208), those with controlled diabetes were older at diagnosis (48.16 years versus 45.38 years, P = 0.0109), were less often treated with insulin (38.84% versus 49.52%, P = 0.0254), had macular edema less often (6.25% versus 14.42%, P = 0.0055), or at least one microvascular complication (20.09% versus 33.65%, P = 0.0015), were very satisfied with treatment more often (65.18% versus 46.63%, P , 0.0001), and forgot less often to take their medication (15.87% versus 25.00%, P = 0.0411).
A logistic regression was run to assess the factors that influence control of HbA 1c (all types of treatment, Table 8 
Predictors of adherence to all types of treatment
Using the MMAS (MMAS = 0), the average age of type 2 diabetes patients adherent to therapy (n = 385) was higher than that of those nonadherent to therapy (n = 121, 60.72 years versus 57.01 years, respectively, P = 0.0008, Table 9 ). The adherent patients were older at diagnosis (47.85 years versus 45.28 years, P = 0.0209), while the adherent group was also more likely to be female than the nonadherent group (36.88% versus 26.45%, P = 0.0282). Socioeconomically, the adherent group was more likely to have an income of €20,000 to <€50,000 (55.84% versus 43.80%, P = 0.0214), as well as being less likely to be employed (23.38% versus 36.36%, P = 0.0087), and were more frequently using insulin (39.48% versus 26.45%, P = 0.0066). In terms of clinical characteristics, the adherent group was less likely to drink alcohol (P = 0.0365), had significantly more myocardial infarction (P = 0.0473), and had more macular edema complications (P = 0.0005). They were more frequently followed up by an endocrinologist or diabetologist (47.53% versus 34.71%, P = 0.0118). We did not see any difference in terms of control of diabetes. A logistic regression showed two significant factors of adherence, ie, older age (OR 1.04, 95% CI 1.011-1.071, P = 0.0075, Table 10 ) and macular edema or diabetic retinopathy (OR 4.282, 95% CI 1.171-15.659, P = 0.0279). Conversely, currently drinking alcohol (OR 0.559, 95% CI 0.319-0.982, P = 0.0429), and HbA 1c .7% (OR 0.551, 95% CI 0.307-0.989, P = 0.0458) were significant predictors of nonadherence.
Insulin did not appear to be a determining factor of adherence when insulin users were compared with all users of oral bitherapy or tritherapy. However, as shown in Table 10 , logistic regression comparing insulin users with uncontrolled oral bitherapy and tritherapy users (n = 256) showed that insulin 
impact of insulin on quality of life
Linear regression models were used to assess the impact of insulin, early insulin initiation, and short (#5 years) insulin duration versus uncontrolled bitherapy and tritherapy users on MCS and PCS scores. Table 11 summarizes the adjusted means for MCS and PCS. Overall, no significant difference was observed between the two groups on the MCS (44.182 versus 45.832), and PCS (39.611 versus 40.093) scores. However, one must note the significant difference (P = 0.0304) on the MCS in the early insulin initiation subgroup, which can be explained by the eventual complications and negative perception of insulin as a last resort treatment. Indeed, there were no significant differences between the early insulin patients with no complications versus patients uncontrolled by bitherapy or tritherapy. As shown in Figure 1 , when the presence or absence of complications were considered, whatever the treatment, the presence of complications had a negative impact on both MCS (42.66 versus 47.36, P , 0.0001) and PCS (34.32 versus 43.48, P , 0.0001). Analysis of MCS and PCS data based on duration of insulin therapy (,3 years, 3-5 years, 6-10 years, $11 years) allowed observation of the stability of quality of life scores on the two dimensions, with the only significant difference on physical health decreasing after 11 years and more of treatment, compared with ,3 years in relation to the appearance of chronic complications (Figure 2 Also, as post hoc analyses, type 2 diabetes quality of life scores were compared with other disease conditions. Figure 3 shows that patients with type 2 diabetes have lower mental health scores (MCS = 45.86) relative to the average person, but higher levels of mental health than people diagnosed with depression, and similar scores relative to patients with metabolic syndrome, allergic rhinitis, or hepatitis C. Patients with type 2 diabetes had lower levels of physical health (PCS = 42.32) relative to the average person and people suffering from allergic rhinitis and depression, but very similar levels of physical health relative to patients with hepatitis C. Also, quite surprisingly, they had higher levels of physical health compared with those having metabolic syndrome.
Discussion
Determinants of insulin prescription
In this study, factors determining insulin prescription in multivariable analysis consisted of lower age at type 2 diabetes diagnosis, the presence of retinopathy, neuropathic pain, being treated by a specialist, and lower (,€50,000 per annum) income. Factors determining early insulin prescription in the course of the disease, as compared with late insulin prescription, were of younger age at diagnosis and had a lower income. When the factors determining early insulin prescription in the course of the disease were analyzed as compared with uncontrolled oral therapy, lower income and being treated by a specialist were observed to be significant. It is not surprising to observe that patients with severe complications are more often treated with insulin; the effect of an early diabetes onset may be explained by the presence of late autoimmune diabetes among the patients in the study, with up to 10% of patients diagnosed with type 2 diabetes found to have anti-glutamic acid decarboxylase antibodies. 26 The higher frequency of specialist care in insulin treated patients must be interpreted with caution. It does not mean that general practitioners are reluctant to prescribe insulin. They may refer the patient to the specialist when they appropriately estimate that insulin should be prescribed: incidentally, this may explain why, in one study, clinical inertia concerning insulin prescription was found to be more frequent among general practitioners than among specialists. 14 The independent effect of patients' income observed herein is more original: our data suggest that patients with a lower income are more frequently treated by insulin. While the deleterious effect of social deprivation on patient adherence is known, 27 whether low income leads to an increased risk of doctors' clinical inertia is harder to determine. For instance, one study showed that patients of low socioeconomic class had diabetes more often and were able to achieve treatment targets less often, but in fact had indicators of good practice more often, ie, measurement of HbA 1c , microalbuminuria, eye examination, treatment by insulin in insufficient control of diabetes. 28 However, a more recent study did not show evidence of a language barrier effect on intensification of therapy in patients with type 2 diabetes imbalance, but a low level of income was clearly associated with less treatment intensification. 29 
Predictors of control of diabetes
In the bivariate analysis, we observed classical determinants of diabetes control, such as diabetes duration, adherence to therapy (the effect of adherence on metabolic control, hypercholesterolemia, and hypertension is also well substantiated), [30] [31] [32] [33] and, as expected, we observed an association of good control with less frequency of diabetic complications.
The strong effect of satisfaction towards treatment is more puzzling: not the fact that controlled patients are more frequently satisfied by their treatment, which seems to hold true. But the fact that in the multivariable analysis this determinant had by far the strongest link with diabetes control, suggesting that other factors (eg, dosage, number of required treatments per day) could be influencing this particular variable.
Predictors of patient adherence
This study confirms the known determinants of adherence observed in the multivariable analysis, ie, older age, [34] [35] [36] [37] abstinence from drinking, 38 metabolic control, 30, 31, 39 and the presence of complications.
37 Surprisingly, we did not observe any association between nonsmoking and adherence, which was shown in some studies. [40] [41] [42] [43] In bivariate analysis, we observed that adherent respondents were less likely to be employed. This was also observed in the recent French ENTRED (Medication Adherence in Type 2 Diabetes) study. 37 In our 
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insulin initiation for type 2 diabetes in France study, adherent patients reported lower income status, while in the ENTRED study, 37 financial difficulties were associated with a low adherence rate, as in a Swedish study. 27 The fact that, in our study, lower income was associated with good adherence is consistent with a Canadian study. 44 The fact that the same findings were observed in France, where diabetic drugs are paid by the social security program, suggests that this effect may not be due to what was observed in Canada (the effect of copayment).
In our study, insulin adherence was better in patients treated with insulin than in those treated with oral antidiabetic medication, especially in the case of early insulin prescription. Indeed, insulin users had 3.0 times greater odds of being adherent compared with uncontrolled oral bitherapy or tritherapy users (OR 2.983, P = 0.0059). Interestingly, the fact that adherence may be better with injections was proposed as an argument to favor injectable rather than oral penicillin in children with impaired splenic function, 45 and it is also a concern when considering adherence to cancer therapy. 46 This better adherence to injectable therapy, observed in our study, is in contradiction with the general concern of physicians concerning patient adherence as a cause of psychological insulin resistance. 47 effect of treatment with insulin on quality of life Overall, no significant difference was observed between insulin users and uncontrolled bitherapy or tritherapy users concerning MCS and PCS scores. Quality of life, both physical and mental, was therefore not altered compared with that in patients uncontrolled on bitherapy or tritherapy. Physical health scores decreased after 11 years of diabetes therapy, possibly an effect of the appearance of chronic complications. The lower MCS score in the early insulin initiation subgroup may also be explained by the eventual presence of complications, which were well analyzed in this study (Figure 1) . Indeed, there were no significant differences for the early insulin patients with no complications versus patients uncontrolled by bitherapy or tritherapy.
In this context of quality of life, reflecting the burden of the disease, it was interesting to compare the European data concerning type 2 diabetes with those of other highprevalence chronic diseases. For this comparison, previous European NHWS studies were prioritized, because the methodology and measures were the same, thus providing the most suitable and relevant basis for comparison with diabetes in the current study. Comparison of scores (Figure 3) shows that the MCS and PCS scores for patients with type 2 diabetes are comparable across other conditions, and patients with type 2 diabetes have relative lower scores than the general population.
Although this study has some weak points, many of the findings are consistent with those reported in the literature. The first limitation is the relatively small number of patients as compared with other studies addressing specific issues, such as patient adherence based on refill evaluation, allowing analysis of much larger populations. Thus, the small sample sizes in the current study precluded the ability to conduct multivariable analyses for specific delays or duration of treatment, or to generalize broadly from the current data. Future research should adjust for possible confounds with larger samples and multivariable analysis.
Secondly, the Internet survey methodology may have introduced bias, explaining for instance the unexpected high male to female ratio observed in this study. The Internet survey was a real limitation in France in 2008, with lower Internet penetration in the female population explaining the overestimation of males in the diabetic population, as in 2010 this bias was less important with a rate of 59% of males much closer to the normal rate of 54% in type 2 diabetes. 37 Also, due to the self-report nature of the current study, no verification of diagnoses, treatment, fasting glucose, HbA 1c level or disease complications was made.
Third, cross-sectional data provide a one-time snapshot of the relationships between study variables. They can suggest directions for further research, but definite claims cannot be made regarding causal relationships among domains (eg, earlier insulin initiation and quality of life or adherence). However, the relevance of this data is strong because of the comparable methodology; 3 years of data can be pulled and a larger sample size is achievable, the patients reported are look ing at many different measures using validated scales (the MMAS and SF-12v2) and even more are looking at treatment satisfaction, all these dimensions that can only have been caught from the patient perspective.
Conclusion
With these limitations in mind, the current study contributes to the growing literature documenting the burden and health effects associated with insulin treatment. There may be a rationale for prescribing insulin earlier than what is done with the current treatment paradigm. 5 Recently, the effect of introducing insulin early in the course of the disease was reported in the ORIGIN (Outcome Reduction with Initial Glargine Intervention insuliN glargine therapy) study. 48 The effect on prevention of mortality was neutral in this study. However, early insulin initiation was shown to be safe, leading to a modest increase in body weight and in the rate of severe hypoglycemia, and was reassuring concerning the risk of cancer. There was a reduction in diabetes incidence in individuals having only prediabetes at entry to the study. Thus, given the potential impact of prescribing insulin earlier, the current paper provides important information regarding the experience of insulin users in France. Finally, the main finding of our study was an unexpected improvement in adherence among insulin-treated patients, and the absence of a deleterious effect on quality of life in patients with no complications. This may represent an argument to fight against psychological insulin resistance.
